Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Enrollment in RAPIDe-3, the pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, continuing as planned; topline data anticipated in 1Q2026 Study initiation of ...

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Astria Therapeutics (ATXS – Research Report). The associated ...

Intellia Therapeutics prioritizes late-stage gene-editing programs for HAE and ATTR amyloidosis in 2025, announces leadership ...

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced its planned design of the ...

Global biopharmaceutical company Takeda recently hosted an event“Innovation and Hope: Connecting Minds to Transform HAE ...